Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26029591 | 0.79 | AOC3 (0.54) | AOC3KMT2AMAPTMAPK1TDP1 | |
| SCHEMBL26030082 | 0.69 | MAOB (0.41) | KMT2AMAPTMAPK1TDP1EPHX2 | |
| SCHEMBL26022218 | 0.68 | TDP1 (0.41) | MAPK1TDP1EPHX2CNR1CNR2 | |
| SCHEMBL26022420 | 0.67 | CNR1 (0.35) | KMT2AMAPTMAPK1TDP1EPHX2 | |
| SCHEMBL26030081 | 0.67 | ACVRL1 (0.40) | KMT2AMAPTMAPK1TDP1EPHX2 | |
| SCHEMBL26022419 | 0.66 | CNR1 (0.34) | KMT2AMAPTMAPK1TDP1EPHX2 | |
| SCHEMBL25903076 | 0.65 | MAPK1 (0.47) | MAPK1TDP1EPHX2CNR1CNR2 | |
| SCHEMBL26028705 | 0.65 | EPHX2 (0.39) | MAPK1TDP1EPHX2CNR1CNR2 | |
| SCHEMBL21340057 | 0.65 | TDP1 (0.50) | KMT2AMAPTMAPK1TDP1EPHX2 | |
| SCHEMBL25903923 | 0.63 | GPR119 (0.49) | KMT2AMAPTMAPK1TDP1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | AOC3 152/4885KMT2A 4715/4885MAPT 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.